Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
Top Page
BioNTech SE
(NASDAQ:BNTX)56Neutral
Positive Factors
Analyst Recommendation
Analyst coverage is initiated with a Buy rating, suggesting a potential 40% upside to a target price of $172.
Product Development
The oncology pipeline, particularly the BNT327 product, is seen as having a significant revenue potential, with BNT327 being potentially first to market in key indications.
Negative Factors
Competitive Risks
Risks include missing COVID vaccine guidance, potential superior data from competitors, and slower-than-expected uptake for new oncology launches.
BioNTech SE (BNTX) vs. S&P 500 (SPY)
Market Cap
$27.51B
Dividend YieldN/A
Average Volume (3M)768.15K
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth-52.11%
EPS Growth-118.03%
CountryUS
Employees6,133
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.10
Shares Outstanding237,766,240
10 Day Avg. Volume898,140
30 Day Avg. Volume768,153
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.89
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$143.98Price Target Upside29.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
BioNTech SE Business Overview & Revenue Model
Company DescriptionBioNTech SE is a German biotechnology company that specializes in the development and manufacturing of active immunotherapies for patient-specific approaches to the treatment of diseases. The company operates in the biotechnology and pharmaceutical sectors, focusing on pioneering research in immunotherapy and innovative medicines for cancer and other serious diseases. BioNTech is known for its mRNA-based vaccine technology, which gained prominence through its collaboration with Pfizer to develop the COVID-19 vaccine.
How the Company Makes MoneyBioNTech generates revenue primarily through the development and commercialization of pharmaceutical products, particularly its mRNA-based vaccines. A significant portion of its income comes from its collaboration agreements, most notably with Pfizer, where BioNTech and Pfizer share the commercial profits from the COVID-19 vaccine, Comirnaty. The company also engages in licensing agreements, research and development collaborations, and manufacturing services, contributing to its revenue streams. Additionally, government contracts and supply agreements for vaccine distribution have been crucial in driving BioNTech's revenue during the COVID-19 pandemic.
BioNTech SE Financial Statement Overview
Summary
BioNTech SE faces a challenging financial trajectory with declining revenues and profitability, reflected in the income statement. The balance sheet remains robust with strong equity and low leverage, providing stability. However, the cash flow statement highlights diminished free cash flow, potentially impacting future growth opportunities. The company must address operational inefficiencies to improve financial health and leverage its strong balance sheet for sustainable growth.Income Statement
BioNTech SE's revenue has declined significantly from 2022 to TTM 2024, with a revenue drop from $17.31 billion to $3.04 billion, indicating a challenging market environment. The company reported negative EBIT and net income margins in TTM 2024, reflecting operational challenges. Despite a strong historical performance, recent margins indicate profitability concerns.45
Neutral
Balance Sheet
The company maintains a strong equity position, with a high equity ratio of 85.33% in TTM 2024, demonstrating financial stability. The debt-to-equity ratio remains low at 0.01, indicating minimal leverage risk. However, the return on equity has turned negative in TTM 2024, suggesting efficiency challenges in utilizing equity to generate profits.75
Positive
Cash Flow
BioNTech SE exhibits a significant decline in free cash flow from $13.21 billion in 2022 to $985 million in TTM 2024, raising concerns about cash generation. The operating cash flow to net income ratio is positive, but the reduction in free cash flow growth could affect future investments and operational flexibility.50
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 3.04B | 3.82B | 17.31B | 18.98B | 482.32M | 108.59M | Gross Profit |
| 2.56B | 3.22B | 12.78B | 15.12B | -222.04M | -135.24M | EBIT |
| -936.70M | 690.40M | 12.64B | 15.28B | -82.42M | -181.52M | EBITDA |
| -370.70M | 1.09B | 12.43B | 15.00B | -105.10M | -152.30M | Net Income Common Stockholders |
| -466.90M | 930.30M | 9.43B | 10.29B | 15.20M | -179.17M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 15.67B | 16.55B | 14.06B | 2.07B | 1.35B | 520.83M | Total Assets |
| 22.26B | 23.01B | 23.28B | 15.83B | 2.32B | 797.65M | Total Debt |
| 236.30M | 219.10M | 212.20M | 301.50M | 240.19M | 68.90M | Net Debt |
| -8.74B | -11.44B | -13.66B | -1.39B | -970.02M | -450.25M | Total Liabilities |
| 2.29B | 2.76B | 3.22B | 3.94B | 946.77M | 304.15M | Stockholders Equity |
| 19.97B | 20.25B | 20.06B | 11.89B | 1.37B | 493.49M |
| Cash Flow | Free Cash Flow | ||||
| 985.26M | 4.67B | 13.21B | 735.70M | -98.92M | -269.62M | Operating Cash Flow |
| 1.54B | 5.37B | 13.58B | 889.70M | -13.47M | -198.54M | Investing Cash Flow |
| -5.38B | -6.95B | -35.30M | -566.10M | -144.85M | -77.11M | Financing Cash Flow |
| -51.50M | -778.60M | -1.42B | 94.20M | 894.73M | 383.29M |
BioNTech SE Technical Analysis
Negative
110.83
Price Trends
116.74
Negative
115.05
Negative
104.69
Positive
Market Momentum
-1.77
Positive
44.80
Neutral
37.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Negative. The current price of 110.83 is below the 20-day moving average (MA) of 115.63, below the 50-day MA of 116.74, and above the 200-day MA of 104.69, indicating a neutral trend. The MACD of -1.77 indicates Positive momentum. The RSI at 44.80 is Neutral, neither overbought nor oversold. The STOCH value of 37.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTX.
BioNTech SE Risk Analysis
BioNTech SE disclosed 109 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioNTech SE Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $147.01B | 18.41 | 9.05% | 6.44% | 8.77% | 272.80% | |
56 Neutral | $27.51B | ― | -2.37% | ― | -52.11% | -118.03% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
48 Neutral | $13.58B | ― | -28.77% | ― | -52.75% | 25.00% | |
40 Underperform | $1.27B | ― | 30.06% | ― | -30.65% | 77.62% | |
40 Underperform | $286.11M | ― | -46.85% | ― | -100.00% | 72.73% | |
33 Underperform | $71.12M | ― | -106.64% | ― | -76.18% | 40.70% |
* Healthcare Sector Average
Performance Comparison
BNTX
BioNTech SE
110.83
19.56
21.43%
INO
Inovio Pharmaceuticals
1.95
-8.23
-80.84%
NVAX
Novavax
7.87
2.42
44.40%
PFE
Pfizer
26.73
1.12
4.37%
BNTC
Benitec Biopharma
12.99
8.10
165.64%
MRNA
Moderna
35.61
-67.42
-65.44%
BioNTech SE Earnings Call Summary
Earnings Call Date: Nov 4, 2024 | % Change Since: -0.58% | Next Earnings Date: Mar 10, 2025
Earnings Call Sentiment Positive
The earnings call reflected a positive sentiment overall, driven by significant revenue growth, advancements in COVID-19 vaccines, and progress within the oncology pipeline. However, there were concerns regarding increased operating costs and contractual disputes. The financial guidance being at the lower end of the range was a noted challenge.Highlights
Significant Revenue Growth
BioNTech reported total revenues of approximately EUR 1.245 billion for Q3 2024, compared to EUR 895 million for the same period in 2023, marking a significant increase attributed to early approvals of variant-adapted COVID-19 vaccines.
COVID-19 Vaccine Advancements
Successfully launched updated COVID-19 vaccines targeting latest variants, with distribution underway globally. Early strain recommendations and approvals enabled timely delivery for vaccination campaigns.
Progress in Oncology Pipeline
Advancements in bispecific immunomodulator BNT327 and mRNA cancer vaccine portfolio, including successful trials in triple-negative breast cancer and small cell lung cancer.
Strong Financial Position
BioNTech's cash and cash equivalents plus security investments reached approximately EUR 17.8 billion as of September 30, 2024, supporting continued investment in R&D.
Innovation in AI Capabilities
Showcased in-house AI company, InstaDeep, highlighting BioNTech's commitment to state-of-the-art AI in medical research and development.
Lowlights
Increase in Operating Costs
Cost of sales increased to approximately EUR 179 million in Q3 2024 from EUR 162 million in the prior year. R&D expenses also rose to approximately EUR 550 million.
Contractual Disputes
BioNTech accrued around EUR 600 million year-to-date for provisions related to contractual disputes with licensees and collaborators.
Guidance at Low End of Range
BioNTech expects full-year 2024 revenues to be at the low end of the guidance range due to low demand and pricing in low and middle-income countries, with anticipated write-downs impacting revenues.
Company Guidance
In the third quarter of 2024, BioNTech reported revenues of approximately EUR 1.245 billion, a significant increase from the EUR 895 million achieved in the same period last year, largely due to the early approvals of their variant-adapted COVID-19 vaccines. The company's cost of sales amounted to EUR 179 million, while R&D expenses rose to EUR 550 million, reflecting progress in clinical trials for oncology pipeline candidates. SG&A expenses decreased to EUR 151 million, and other operating results were negatively impacted by EUR 355 million due to accruals for contractual disputes. BioNTech reported a net income of EUR 198 million, with diluted earnings per share of EUR 0.81, and maintained a robust cash position of EUR 17.8 billion. The company adjusted its full-year revenue guidance to the lower end of its previous range, citing risks of write-downs and other charges, and decreased its SG&A and capital expenditures guidance by EUR 100 million each, while maintaining its R&D expense guidance.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.